Download PDF
Pharmacopsychiatry 2016; 49(03): 117-123
DOI: 10.1055/s-0035-1569360
Original Paper
© Georg Thieme Verlag KG Stuttgart · New York

Brief Questionnaire Derived from PANSS Using a General Probability Model to Assess and Monitor the Clinical Features of Schizophrenia

S. Ji   #
1   State Key Laboratory of Natural and Biomimetic Drugs, Peking University, Beijing, China
4   School of Pharmaceutical Sciences, Peking University, Beijing, China
,
A. Li   #
2   Center of Schizophrenia, Beijing Institute for Brain Disorders, Laboratory of Brain Disorders (Capital Medical University), Beijing, China
3   Beijing Anding Hospital, Capital Medical University, Beijing, China
,
K. Wu
1   State Key Laboratory of Natural and Biomimetic Drugs, Peking University, Beijing, China
4   School of Pharmaceutical Sciences, Peking University, Beijing, China
,
C. Deng
5   Department of Pharmaceutical Biosciences, Uppsala University, Uppsala, Sweden
,
F. Dong
2   Center of Schizophrenia, Beijing Institute for Brain Disorders, Laboratory of Brain Disorders (Capital Medical University), Beijing, China
3   Beijing Anding Hospital, Capital Medical University, Beijing, China
,
L. Li
1   State Key Laboratory of Natural and Biomimetic Drugs, Peking University, Beijing, China
4   School of Pharmaceutical Sciences, Peking University, Beijing, China
,
T. Zhou
1   State Key Laboratory of Natural and Biomimetic Drugs, Peking University, Beijing, China
4   School of Pharmaceutical Sciences, Peking University, Beijing, China
,
W. Yue
6   Institute of Mental Health, The Sixth Hospital, Peking University, Beijing, China
,
C.-Y. Wang   *
2   Center of Schizophrenia, Beijing Institute for Brain Disorders, Laboratory of Brain Disorders (Capital Medical University), Beijing, China
3   Beijing Anding Hospital, Capital Medical University, Beijing, China
,
W. Lu   *
1   State Key Laboratory of Natural and Biomimetic Drugs, Peking University, Beijing, China
2   Center of Schizophrenia, Beijing Institute for Brain Disorders, Laboratory of Brain Disorders (Capital Medical University), Beijing, China
4   School of Pharmaceutical Sciences, Peking University, Beijing, China
› Author Affiliations
Further Information

Publication History

received 18 August 2015
revised 30 November 2015

accepted 03 December 2015

Publication Date:
25 January 2016 (online)

Also available at
   Permissions and Reprints

Abstract

Aim: Patients with schizophrenia require continuous treatment much longer than the duration of their hospitalization, which makes their family members essential in their medical care. However, the evaluation of the disease state could only be done by professionals. This prompted us to seek potent indicators of disease states that are understandable and easy to use for the patients’ family.

Method: Specific items were firstly extracted from the total PANSS scale. Then 3 096 PANSS scores were analyzed using a nonlinear mixed-effects model (NONMEM). A questionnaire was subsequently developed for family members to assess and monitor the overall severity of schizophrenia. Finally this questionnaire was validated in 33 patients.

Results: 2 items (P1 and N4) were extracted from the 8 effective remission items according to the correlation coefficients between the total PANSS score and different combinations of items. P1N4 was defined as the sum of these 2 items. A model was then developed to describe the probability of PANSS≥60, with P1N4 as indicators. The results indicated that P1N4 could make a good predictor of the overall probability of PANSS≥60, which was independent of treatment. A brief questionnaire with 7 questions was developed based on the results. External validation results indicated the questionnaire’s suitability for a good assessment.

Conclusion: Questionnaire developed based on P1 and N4 may facilitate the patients’ family members to better understand the disease state and help to prevent relapse.

Key words

schizophrenia - nonlinear mixed-effects modeling (NONMEM) - probability model

# To whom correspondence should be addressed


* These authors contributed equally to this paper


 

  • References

  • 1 Picchioni MM, Murray RM. Schizophrenia. BMJ 2007; 335: 91-95
    CrossrefPubMedSearch in Google Scholar
  • 2 Salkever DS, Karakus MC, Slade EP et al. Measures and predictors of community-based employment and earnings of persons with schizophrenia in a multisite study. Psychiatr Serv 2007; 58: 315-324
    CrossrefPubMedSearch in Google Scholar
  • 3 Bond GR, Drake RE. Predictors of competitive employment among patients with schizophrenia. Curr Opin Psychiatry 2008; 21: 362-369
    CrossrefPubMedSearch in Google Scholar
  • 4 Van Os J, Kapur S. Schizophrenia. Lancet 2009; 374: 635-645
    Search in Google Scholar
  • 5 Hor K, Taylor M. Suicide and schizophrenia: a systematic review of rates and risk factors. J Psychopharmacol 2010; 24: 81-90
    CrossrefPubMedSearch in Google Scholar
  • 6 Newman JM, Turnbull A, Berman BA et al. Impact of traumatic and violent victimization experiences in individuals with schizophrenia and schizoaffective disorder. J Nerv Ment Dis 2010; 198: 708-714
    CrossrefPubMedSearch in Google Scholar
  • 7 Leucht S, Corves C, Arbter D et al. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet 2009; 373: 31-41
    Search in Google Scholar
  • 8 Leucht S, Cipriani A, Spineli L et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet 2013; 382: 951-962
    Search in Google Scholar
  • 9 Zhang YS, Si TM, Li KQ. A survey of antipsychotic usage in treatment of schizophrenia in China 2006. Chinese Mental Health Journal 2012; 26: 736-740
    PubMedSearch in Google Scholar
  • 10 Schizophrenia. http://www.mentalhealth.com/home/dx/schizophrenia_advanced.html
    PubMed
  • 11 Magliano L, Fiorillo A, De Rosa C et al. The National Mental Health Project Working Group. Family burden in long-term diseases: A comparative study in schizophrenia vs. physical disorders. Soc Sci Med 2005; 61: 313-322
    CrossrefPubMedSearch in Google Scholar
  • 12 Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 1987; 13: 261-276
    Search in Google Scholar
  • 13 Kay SR, Opler LA, Lindenmayer JP. The Positive and Negative Syndrome Scale (PANSS): rationale and standardization. Br J Psychiatry Suppl 1989; 7: 59-67
    PubMedSearch in Google Scholar
  • 14 Lindenmayer JP, Harvey PD, Khan A et al. Schizophrenia: measurements of psychopathology. Psychiatr Clin North Am 2007; 30: 339-363
    CrossrefPubMedSearch in Google Scholar
  • 15 Opler MG, Yang LH, Caleo S et al. Statistical validation of the criteria for symptom remission in schizophrenia: preliminary findings. BMC Psychiatry 2007; 7: 35
    CrossrefPubMedSearch in Google Scholar
  • 16 Li WS, Zhao Y, Fang W. The effect of group psychotherapy on improving the symptoms of middle-aged or youth schizophrenia patients. China Journal of Health Psychology 2014; 22: 331-333
    PubMedSearch in Google Scholar
  • 17 Zhang CG, Wei BY, Zhang R. Clinical observation of aripiprazole in the treatment of schizophrenia. J Clin Psychosom Dis 2005; 11: 223-224
    PubMedSearch in Google Scholar
  • 18 Leucht S, Kane JM, Kissling W et al. What does the PANSS mean?. Schizophr Res 2005; 79: 231-238
    CrossrefPubMedSearch in Google Scholar
  • 19 Jenkins JH, Carpenter-Song E. The new paradigm of recovery from schizophrenia: cultural conundrums of improvement without cure. Cult Med Psychiatry 2005; 29: 379-413
    CrossrefPubMedSearch in Google Scholar
  • 20 Caqueo-Urizar A, Rus-Calafell M, Urzua A et al. The role of family therapy in the management of schizophrenia: challenges and solutions. Neuropsychiatr Dis Treat 2015; 11: 145-151
    PubMedSearch in Google Scholar
  • 21 Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry 1979; 134: 382-389
    CrossrefPubMedSearch in Google Scholar
  • 22 Montgomery SA, Taylor P, Montgomery D. Development of a schizophrenia scale sensitive to change. Neuropharmacology 1978; 17: 1061-1063
    CrossrefPubMedSearch in Google Scholar
  • 23 Seo JM, Byun EK, Park KY et al. Development of a coping scale for families of patients with schizophrenia. Journal of Korean Academy of Nursing 2012; 42: 738-748
    CrossrefPubMedSearch in Google Scholar
  • 24 Yamamoto N, Inada T, Shimodera S et al. Brief PANSS to assess and monitor the overall severity of schizophrenia. Psychiatry Clin Neurosci 2010; 64: 262-267
    CrossrefPubMedSearch in Google Scholar
  • 25 Andreasen NC, Carpenter Jr WT, Kane JM et al. Remission in schizophrenia: proposed criteria and rationale for consensus. Am J Psychiatry 2005; 162: 441-449
    CrossrefPubMedSearch in Google Scholar
  • 26 Chan HY, Lin AS, Chen KP et al. An open-label, randomized, controlled trial of zotepine and risperidone for acutely ill, hospitalized, schizophrenic patients with symptoms of agitation. J Clin Psychopharmacol 2013; 33: 747-752
    CrossrefPubMedSearch in Google Scholar
  • 27 Canuso CM, Schooler N, Carothers J et al. Paliperidone extended-release in schizoaffective disorder: a randomized, controlled study comparing a flexible dose with placebo in patients treated with and without antidepressants and/or mood stabilizers. J Clin Psychopharmacol 2010; 30: 487-495
    CrossrefPubMedSearch in Google Scholar
  • 28 Takahashi N, Takahashi M, Saito T et al. Randomized, placebo-controlled, double-blind study assessing the efficacy and safety of paliperidone palmitate in Asian patients with schizophrenia. Neuropsychiatr Dis Treat 2013; 8: 1889-1898
    PubMedSearch in Google Scholar
  • 29 Yue WH, Wang HF, Sun LD et al. Genome-wide association study identifies a susceptibility locus for schizophrenia in Han Chinese at 11p11.2. Nature Genetics 2011; 43: 1228-1231
    CrossrefPubMedSearch in Google Scholar
  • 30 Wang W, Chen QS, Liu ZM. To calculate and evaluate the ICC using Excel. Chin J Hlt Stat 2008; 25: 314-315
    PubMedSearch in Google Scholar
  • 31 Yu HM, Luo YH, Sa J et al. To calculate ICC using different software. Chin J Hlt Stat 2011; 28: 497-499
    PubMedSearch in Google Scholar